Dr. Borghaei on 2-Year Findings With Nivolumab Vs Docetaxel in NSCLC

Hossein Borghaei, DO
Published: Friday, Jun 03, 2016

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor in the Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the phase III CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non–small cell lung cancer (NSCLC).

Patients enrolled on the CheckMate-017 study were diagnosed with squamous NSCLC, while those enrolled in the CheckMate-057 study had nonsquamous NSCLC, Borghaei explains. Two-year results showed that nivolumab significantly improved overall survival compared with docetaxel in both studies. This demonstrates that, in the second-line setting, the single-agent has a long-term benefit in these patients.

Additional cytokine analyses that coincide with these data show that patients who harbor cytokine expression will generally have a more durable response with nivolumab, he adds.

<<< View more from the 2016 ASCO Annual Meeting

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor in the Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the phase III CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non–small cell lung cancer (NSCLC).

Patients enrolled on the CheckMate-017 study were diagnosed with squamous NSCLC, while those enrolled in the CheckMate-057 study had nonsquamous NSCLC, Borghaei explains. Two-year results showed that nivolumab significantly improved overall survival compared with docetaxel in both studies. This demonstrates that, in the second-line setting, the single-agent has a long-term benefit in these patients.

Additional cytokine analyses that coincide with these data show that patients who harbor cytokine expression will generally have a more durable response with nivolumab, he adds.

<<< View more from the 2016 ASCO Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x